Hacettepe University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey
Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey
Turk J Ophthalmol. 2020 Oct 30;50(5):258-263. doi: 10.4274/tjo.galenos.2020.37346.
Topical application of fluoroquinolone antibiotics is thought to be as effective as fortified antibiotics. The aim of this study was to evaluate the efficacy of fluoroquinolones as an alternative to fortified antibiotic therapies.
The medical records of 31 patients who were hospitalized in our department due to bacterial keratitis were retrospectively reviewed. Fluoroquinolone was started as the first treatment for 20 (64.5%) patients and upon no response fortified antibiotic was initiated, and 11 (35.5%) patients were started with fortified treatment. Cultures and smears were recorded before treatment. Lesions were evaluated as superficial or deep according to their depth. Treatment response was evaluated based on reduction of infiltrate depth and size, change in visual acuity, and regression of hypopyon.
Central, paracentral, and peripheral location were detected in 9 (29.0%), 10 (32.2%) and 12 (38.7%) eyes, respectively. According to lesion depth, 15 (48.3%) were deep and 16 (51.6%) were superficial. Response of superficial lesions was found to be statistically earlier (p=0.037). Culture was positive in 9 (29.0%) eyes. The initial best corrected visual acuity (BCVA) was 0.5±0.7 logMAR (-0.1-2.3) and 0.3±0.3 logMAR (-0.1-0.9) after treatment. Treatment response showed moderate but statistically nonsignificant correlation with time to treatment initiation and initial BCVA (r=0.527, p=0.184; r=0.517, p=0.120).
Although fluoroquinolones are the first choice for the treatment of bacterial keratitis, fortified antibiotics have been shown to be effective in patients who do not respond to treatment. Fortified therapy should be kept in mind in the treatment of bacterial keratitis.
局部应用氟喹诺酮类抗生素被认为与强化抗生素一样有效。本研究旨在评估氟喹诺酮类药物替代强化抗生素治疗的效果。
回顾性分析因细菌性角膜炎在我科住院的 31 例患者的病历。20 例(64.5%)患者开始使用氟喹诺酮类药物作为一线治疗,无反应时开始强化抗生素治疗,11 例(35.5%)患者开始强化治疗。记录治疗前的培养物和涂片。根据病变深度将病变分为浅层或深层。根据浸润深度和大小的减少、视力的变化和前房积脓的消退来评估治疗反应。
9 只眼(29.0%)、10 只眼(32.2%)和 12 只眼(38.7%)分别位于中央、旁中央和周边位置。根据病变深度,15 只眼(48.3%)为深层,16 只眼(51.6%)为浅层。浅层病变的反应明显更早(p=0.037)。9 只眼(29.0%)培养阳性。初始最佳矫正视力(BCVA)为 0.5±0.7 logMAR(-0.1-2.3),治疗后为 0.3±0.3 logMAR(-0.1-0.9)。治疗反应与治疗开始时间和初始 BCVA 呈中度但无统计学意义的相关性(r=0.527,p=0.184;r=0.517,p=0.120)。
虽然氟喹诺酮类药物是细菌性角膜炎的首选治疗药物,但强化抗生素对治疗无反应的患者也有效。在细菌性角膜炎的治疗中应考虑强化治疗。